Moderna's vaccine approved in the EU
EMA's evaluation of the vaccine has shown that it meets the EU's requirements for safety, efficacy, quality and manufacturing. This is the second COVID-19 vaccine to be approved by the European Commission.
– Moderna's vaccine is based on the same technology platform as the previously approved Comirnaty vaccine. The new vaccine provides 94 per cent protection against COVID-19 and has shown an expected and acceptable side-effect profile," says Charlotta Bergquist, vaccine coordinator at the Swedish Medical Products Agency.
The clinical trials, with approximately 30,000 participants, investigated how well Moderna's vaccine protected people who had not had COVID-19 previously. Overall, the study showed that the vaccine provides 94 per cent protection against COVID-19.
Approved Swedish product information for the vaccine will be published as soon as possible, writes the Swedish Medical Products Agency. It concerns information for healthcare professionals, a patient information leaflet for the general public and information on the conditions associated with the approval of the vaccine.